HYSINGLA ER

12345678910111213141516171819
Across
  1. 2. Frequency of HYSINGLA ER dosing
  2. 5. Do this by 25% to the calculated oral hydrocodone dose in opioid tolerant patients
  3. 6. _____ properties that are expected to deter intranasal and intravenous abuse
  4. 8. Clinical trials conducted in opioid ____ and opioid _______
  5. 9. This pain type was evaluated in the HYSINGLA ER pivotal efficacy trial (12-Week Study)
  6. 11. Abuse deterrent technology
  7. 12. Starting dose in opioid naive
  8. 13. This is a differentiating characteristic of Hysingla ER
  9. 14. Percentage of HYSINGLA ER patients who completed the double-blind, 12-week treatment
  10. 16. Initiation of CYP3A4 _______ can result in fatal overdose of hydrocodone from Hysingla ER
  11. 18. 1:1 conversion from any other __________ product
  12. 19. Mean terminal half-life at steady state
Down
  1. 1. Median TMax values on both Day 1 and Day 5
  2. 3. HYSINGLA ER is indicated for use when these treatment options are inadequate
  3. 4. ____ _____ the continued need for the use of opioid analgesics
  4. 7. _____ _____ strengths allows for individualized treatment
  5. 10. Hysingla ER contains none of this analgesic
  6. 15. Recommended frequency for adjusting the HYSINGLA ER dose as needed is every ____ __ ____ days
  7. 17. Hysingla ER provides 24-hour delivery of